Nicholas Tatonetti

Scientific Advisor at CARI Health
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
New York, New York, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Scientific Advisor
      • Oct 2023 - Present

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Vice Chair, Department of Computational Biomedicine
      • Jan 2023 - Present

    • Associate Director
      • Jan 2023 - Present

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Chief Officer for Cancer Data Science
      • Apr 2022 - Jan 2023

    • United States
    • Higher Education
    • 700 & Above Employee
    • Associate Professor
      • Jul 2019 - Jan 2023

    • United States
    • Technology, Information and Internet
    • 700 & Above Employee
    • Founder
      • Jan 2018 - Dec 2021

      Founded a biotechnology startup in the drug development and drug toxicity space. Founded a biotechnology startup in the drug development and drug toxicity space.

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Assistant Professor of Biomedical Informatics
      • Sep 2012 - Jul 2019

    • United States
    • Software Development
    • 100 - 200 Employee
    • Clinical Data Analysis Consultant
      • May 2012 - Jul 2012

    • United States
    • Higher Education
    • 700 & Above Employee
    • Graduate Student
      • 2008 - Jun 2012

      My work focuses on developing rigorous statistical and computational models for addressing these primary shortcomings of observational data analysis in the context of disease risk and drug response. In my thesis work I developed novel statistical and computational algorithms to analyze large scale clinical databases for drug-drug interaction discovery. I uncovered an unexpected interaction between paroxetine and pravastatin using these methods and validated the interaction in a… Show more My work focuses on developing rigorous statistical and computational models for addressing these primary shortcomings of observational data analysis in the context of disease risk and drug response. In my thesis work I developed novel statistical and computational algorithms to analyze large scale clinical databases for drug-drug interaction discovery. I uncovered an unexpected interaction between paroxetine and pravastatin using these methods and validated the interaction in a retrospective analysis of three independent hospital record systems. Finally, I developed tools for uncovering the molecular etiology of adverse events and applied them to mined drug-drug interactions. Show less My work focuses on developing rigorous statistical and computational models for addressing these primary shortcomings of observational data analysis in the context of disease risk and drug response. In my thesis work I developed novel statistical and computational algorithms to analyze large scale clinical databases for drug-drug interaction discovery. I uncovered an unexpected interaction between paroxetine and pravastatin using these methods and validated the interaction in a… Show more My work focuses on developing rigorous statistical and computational models for addressing these primary shortcomings of observational data analysis in the context of disease risk and drug response. In my thesis work I developed novel statistical and computational algorithms to analyze large scale clinical databases for drug-drug interaction discovery. I uncovered an unexpected interaction between paroxetine and pravastatin using these methods and validated the interaction in a retrospective analysis of three independent hospital record systems. Finally, I developed tools for uncovering the molecular etiology of adverse events and applied them to mined drug-drug interactions. Show less

    • Biotechnology
    • Chief Executive Officer
      • Mar 2009 - Jan 2012

  • Mophilia, Inc.
    • Mountain View, CA
    • Chief Science Officer
      • Feb 2009 - Apr 2010

    • Owner/Operator
      • Jan 2003 - Mar 2008

    • Book and Periodical Publishing
    • 1 - 100 Employee
    • Chief Technical Officer
      • 2007 - 2008

Education

  • Stanford University
    PhD, Biomedical Informatics
    2008 - 2012
  • Stanford University
    MS, Biomedical Informatics
    2008 - 2011
  • Arizona State University
    BS, Molecular Biosciences / Biotechnology
    2005 - 2008
  • Arizona State University
    BS, Computational Mathematics
    2005 - 2008

Community

You need to have a working account to view this content. Click here to join now